To main content To main navigation

Hilde Jalving

Internist-oncologist Profile

Internist-oncologist

Contact information

Discover our research

Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I study

2024, Nature Communications

Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy

2024, ESMO Open

All publications

- Cutaneous squamous cell carcinomaHilde Jalving (Invited speaker) 15-Sep-2024 Professional or public presentation > Professional
- Discussion: How can ESMO support you in making your practice more sustainable?Hilde Jalving (Invited speaker) 14-Sep-2024 Professional or public presentation > Professional
- Moving towards a sustainable academic society: Update from the ESMO Climate Change Task ForceHilde Jalving (Invited speaker) 14-Sep-2024 Professional or public presentation > Professional
- Behandeling melanoom in stadium III/IVHilde Jalving (Invited speaker) 6-Apr-2024 Professional or public presentation > Professional
- Nadina Studie update - (neo )adjuvante behandeling van melanoomHilde Jalving (Invited speaker) 6-Apr-2024 Professional or public presentation > Professional
All activities
- Young Investigator Grant DutchHilde Jalving, 2017 Academic
All prizes

Contact